Investigating the potential effects of selective histone deacetylase 6 inhibitor ACY1215 on infarct size in rats with cardiac ischemia-reperfusion injury

Chao-Feng Lin,Shiow-Lin Pan,Han-Li Huang,Tony Eight Lin,Kai-Cheng Hsu,Wei-Chun Huangfu

doi:10.1186/s40360-020-0400-0

Chao-Feng Lin, Shiow-Lin Pan + Show 4 more

Open Access

https://doi.org/10.1186/s40360-020-0400-0

Copy DOI

Abstract

BackgroundDespite the fact that histone deacetylase (HDAC) inhibitors have been tested to treat various cardiovascular diseases, the effects of selective HDAC6 inhibitor ACY1215 on infarct size during cardiac ischemia-reperfusion (IR) injury still remain unknown. In the present study we aimed to investigate the effects of ACY1215 on infarct size in rats with cardiac IR injury, as well as to examine the association between HDAC6 inhibitors and the gene expression of hypoxia inducible factor-1α (HIF-1α), a key regulator of cellular responses to hypoxia.MethodsBy using computational analysis of high-throughput expression profiling dataset, the association between HDAC inhibitors (pan-HDAC inhibitors panobinostat and vorinostat, and HDAC6 inhibitor ISOX) and their effects on HIF-1α gene-expression were evaluated. The male Wistar rats treated with ligation of left coronary artery followed by reperfusion were used as a cardiac IR model. ACY1215 (50 mg/kg), pan-HDAC inhibitor MPT0E028 (25 mg/kg), and vehicle were intraperitoneally injected within 5 min before reperfusion. The infarct size in rat myocardium was determined by 2,3,5-triphenyltetrazolium chloride staining. The serum levels of transforming growth factor-β (TGF-β) and C-reactive protein (CRP) were also determined.ResultsThe high-throughput gene expression assay showed that treatment of ISOX was associated with a more decreased gene expression of HIF-1α than that of panobinostat and vorinostat. Compared to control rats, ACY1215-treated rats had a smaller infarct size (49.75 ± 9.36% vs. 19.22 ± 1.70%, p < 0.05), while MPT0E028-treated rats had a similar infarct size to control rats. ACY-1215- and MPT0E028-treated rats had a trend in decreased serum TGF-β levels, but not statistically significant. ACY1215-treated rats also had higher serum CRP levels compared to control rats (641.6 μg/mL vs. 961.37 ± 64.94 μg/mL, p < 0.05).ConclusionsOur research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1α expression. TGF-β and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury.

Highlights

Despite the fact that histone deacetylase (HDAC) inhibitors have been tested to treat various cardiovascular diseases, the effects of selective HDAC6 inhibitor ACY1215 on infarct size during cardiac ischemiareperfusion (IR) injury still remain unknown
Despite successful reperfusion of occluded coronary arteries, ischemic cardiomyocyte death followed by reperfusion may result in ischemiareperfusion (IR) injury that lead to expansion of infarct size, post-Myocardial infarction (MI) cardiac fibrosis, and ventricular dysfunction [2, 3]
This analysis indicated that HDAC inhibitors might play roles in cardiac IR injury

Summary

Introduction

Despite the fact that histone deacetylase (HDAC) inhibitors have been tested to treat various cardiovascular diseases, the effects of selective HDAC6 inhibitor ACY1215 on infarct size during cardiac ischemiareperfusion (IR) injury still remain unknown. In the present study we aimed to investigate the effects of ACY1215 on infarct size in rats with cardiac IR injury, as well as to examine the association between HDAC6 inhibitors and the gene expression of hypoxia inducible factor-1α (HIF-1α), a key regulator of cellular responses to hypoxia. Despite successful reperfusion of occluded coronary arteries, ischemic cardiomyocyte death followed by reperfusion may result in ischemiareperfusion (IR) injury that lead to expansion of infarct size, post-MI cardiac fibrosis, and ventricular dysfunction [2, 3]. The myocardium jeopardized in IR injury is characterized by an enhanced expression of transforming growth factor-β (TGF-β), myofibrillar destruction, and infiltrating leukocytes. These mentioned histological signs become more manifest during reperfusion than that during ischemia [2, 4]. Pharmacological interventions to reduce infarct size by modulating the expression of HIF-1α and TGF-β are potential strategies to diminish cardiac IR injury and preserve ventricular function

Objectives

Methods

Results

Discussion

Conclusion